期刊文献+

组蛋白修饰相关基因对前列腺癌细胞DU145活性的影响 被引量:1

The effect of genes involved in histone modification on the viability of prostate cancer cells
原文传递
导出
摘要 目的 观察组蛋白修饰相关基因对前列腺癌细胞DU145活性的影响.方法 利用短发夹RNA (shRNA)使前列腺癌细胞DU145的44种组蛋白修饰相关基因发生沉默,观察哪些基因对DU145增殖呈正向调节作用.结果 44种组蛋白修饰相关基因中的9种基因[极光激酶A(AURKA)、组蛋白调节基因(HIRA)、多梳增强子1基因(EPC1)、拟南芥驱动蛋白2A基因(KAT2A)、拟南芥驱动蛋白2B基因(KAT2B)、拟南芥驱动蛋白5基因(KAT5)、拟南芥驱动蛋白6B基因(KAT6B)、组蛋白去乙酰化酶1基因(HDAC1)、组蛋白去乙酰化酶6基因(HDAC6)]对DU145细胞的增殖起到正向调节作用.9种基因中,4个挑选出来的基因:KAT2B、KAT5、KAT6B和HDAC1以基因特异性的方式,对DU145细胞活性的抑制率分别为41%、61%、36%和20% (P<0.05).结论 KAT2B、KAT5、KAT6B和HDAC1作为组蛋白修饰相关基因,可以基因特异性的方式促进前列腺癌细胞DU145的增殖. Objective To observe the role played by genes involved in histone modification in viability of prostate cancer cells.Methods An RNAi screening with 44 genes involved in histone modifications was applied to a prostate cancer cell line,DU145.Results Nine genes [aurora kinase A (AURKA),histone regulation (HIRA),enhancer of polycomb (EPC1),kinesins from arabidopsis thaliana (KAT2A),kinesins from arabidopsis thaliana (KAT2B),kinesins from arabidopsis thaliana (KAT5),kinesins from arabidopsis thaliana (KAT6B),histone deacetylase 1 (HDAC1),histone deacetylase 6 (HDAC6)] could positively regulate the proliferation of DU145 cells (P < 0.05),and four selected genes (KAT2B,KAT5,KAT6B and HDAC1) were found to exert this effect by a gene-specific manner when silenced with a inhibition rate of 41%,61%,36% and 20% (P < 0.05).Conclusion As histone modification genes,KAT2B,KAT5,KAT6B and HDAC1 might promote the proliferation of DU145 cells.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2015年第6期1282-1284,共3页 Chinese Journal of Experimental Surgery
基金 上海市科委资助项目(13DZ1941208)
关键词 前列腺癌 组蛋白修饰 基因沉默 Prostate cancer Histone modification Gene silence
  • 相关文献

参考文献14

二级参考文献40

  • 1汪建平,元云飞.结直肠癌DNA甲基化研究的现状[J].中华实验外科杂志,2004,21(10):1279-1280. 被引量:12
  • 2张群华.我国胰腺外科研究的新进展[J].中华实验外科杂志,2005,22(4):391-392. 被引量:12
  • 3王爱东,黄强.表观遗传学改变与胶质瘤发生的分子关系[J].中华实验外科杂志,2006,23(12):1581-1582. 被引量:6
  • 4甘琳,李鸣.雄激素非依赖性前列腺癌发病机制的研究进展[J].中华外科杂志,2007,45(8):562-564. 被引量:4
  • 5Momparler RL, Bouffard DY, Momparler LF, et al. Pilot phase I - II study on 5-aza-2' -deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs, 1997,8:358-368.
  • 6Shang DH, Noriyuki I, Toshiyuki K, et al. Demethylating agent 5-aza- 2' -deoxycytidine enhances susceptibility of renal cell carcinoma to pa- clitaxel. Urology ,2007,69 : 1007-1012.
  • 7Liu JW, Nagpal JK, Jeronimo C, et al. Hypermethylation of MCAM gene is associated with advanced tumor stage in prostate cancer. Prostate ,2008,68:418-426.
  • 8Kantarjian H,Oki Y,Garcia-Manero G,et al. Results of a randomized study of schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood ,2007,109: 52-57.
  • 9Baylin S B,Cancer Cells,1991年,3卷,383页
  • 10Bimey E,Stamatoyannopoulos JA,Dutta A,et al. Identification and analysis of function-al elements in 1% of the human genome bythe ENCODE pilot project. Nature, 2007 ,447:799-816.

共引文献18

同被引文献3

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部